1 |
Anstee QM, Reeves HL, Kotsiliti E,et al.From NASH to HCC:current concepts and future challenges [J].Nat Rev Gastroenterol Hepatol,2019,16(7):411-428.
|
2 |
Argyrou C, Moris D, Vernadakis S.Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis,prevention and treatment [J].J BUON,2017,22(1):6-20.
|
3 |
Eslam M, Newsome PN, Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement [J].J Hepatol,2020,73(1):202-209.
|
4 |
Degasperi E, Colombo M.Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease [J].Lancet Gastroenterol Hepatol,2016,1(2):156-164.
|
5 |
Umano GR, Caprio S, Di Sessa A,et al.The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth [J].Am J Gastroenterol,2018,113(3):376-383.
|
6 |
Donati B, Dongiovanni P, Romeo S,et al.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals[J].Sci Rep,2017,7(1):4492.
|
7 |
Sutti S, Albano E.Adaptive immunity:an emerging player in the progression of NAFLD [J].Nat Rev Gastroenterol Hepatol,2020,17(2):81-92.
|
8 |
Wu WKK, Zhang L, Chan MTV.Autophagy,NAFLD and NAFLD-Related HCC [J].Adv Exp Med Biol,2018,1061:127-138.
|
9 |
Borrelli A, Bonelli P, Tuccillo FM,et al.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches [J].Redox Biol,2018,15:467-479.
|
10 |
Chow MD, Lee YH, Guo GL.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J].Mol Aspects Med,2017,56:34-44.
|
11 |
Pennisi G, Celsa C, Giammanco A,et al.The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease:Screening Issue and Future Perspectives [J].Int J Mol Sci,2019,20(22):5613.
|
12 |
Hashimoto E, Yatsuji S, Tobari M,et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis [J].J Gastroenterol,2009,44 Suppl 19:89-95.
|
13 |
Kawamura Y, Arase Y, Ikeda K,et al.Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma[J].Am J Gastroenterol,2012,107(2):253-261.
|
14 |
Golabi P, Rhea L, Henry L, Younossi ZM.Hepatocellular carcinoma and non-alcoholic fatty liver disease [J].Hepatol Int,2019,13(6):688-694.
|
15 |
Than NN, Ghazanfar A, Hodson J,et al.Comparing clinical presentations,treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease [J].QJM,2017,110(2):73-81.
|
16 |
Tan H, Xu L, Liu X,et al.Hepatocellular carcinoma in nonalcoholic fatty liver disease mimicking benign hemangioma:two case reports and literature review [J].Int J Clin Exp Pathol,2015,8(11):15350-15355.
|
17 |
Al-Sharhan F, Dohan A, Barat M,et al.MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis(NASH)[J].Eur J Radiol,2019,119:108648.
|
18 |
Garcovich M, Faccia M, Meloni F,et al.Contrast-enhanced ultrasound patterns of hepatocellular adenoma:an Italian multicenter experience [J].J Ultrasound,2019,22(2):157-165.
|
19 |
Hwang A, Shi C, Zhu E,et al.Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis;An OAD to NASH[J].PLoS One,2018,13(6):e0198937.
|
20 |
Montagnana M, Danese E, Lippi G.Squamous cell carcinoma antigen in hepatocellular carcinoma:Ready for the prime time [J]? Clin Chim Acta,2015,445:161-166.
|
21 |
Gori M, Arciello M, Balsano C.MicroRNAs in nonalcoholic fatty liver disease:novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma[J].Biomed Res Int,2014:741465.
|
22 |
Ye J, Li T S, Xu G,et al.JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity [J].Cancer Res,2017,77(19):5287-5300.
|
23 |
Nakamura N, Hatano E, Iguchi K,et al.Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease:from pig model to human study [J].BMC Cancer,2019,19(1):621.
|
24 |
Best J, Bechmann L P, Sowa J P,et al.GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J].Clin Gastroenterol Hepatol,2020,18(3):728-735.
|
25 |
朱风尚,杨长青,陈锡美.非酒精性脂肪性肝炎肝纤维化血清学无创诊断[J/CD].中华消化病与影像杂志(电子版),2014,3(6):38-41.
|
26 |
Yoneda M, Imajo K, Eguchi Y,et al.Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels [J].J Gastroenterol,2013,48(9):1051-1060.
|
27 |
Hsu C Y, Lee Y H, Liu P H,et al.Decrypting cryptogenic hepatocellular carcinoma:clinical manifestations,prognostic factors and long-term survival by propensity score model [J].PLoS One,2014,9(2):e89373.
|
28 |
Lim C, Bhangui P, Salloum C,et al.Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma [J].J Hepatol,2018,68(1):100-108.
|
29 |
寇昌华,韩锡林,庄惠杰,等.脂肪肝合并肝癌患者接受根治术后的临床疗效与安全性分析[J].中国现代医生,2017,55(30):8-10.
|
30 |
Koh Y X, Tan H J, Liew Y X,et al.Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma [J].J Am Coll Surg,2019,229(5):467-478.
|
31 |
刘晓燕,李胜棉,杨俭.1293例原发性肝癌患者非酒精性脂肪性肝病的伴发率及预后特征[J].临床肝胆病杂志,2010,26(6):641-643.
|
32 |
Xu W, Zhang X, Wu J L,et al.O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress[J].J Hepatol,2017,67(2):310-320.
|
33 |
Okada H, Takabatake R, Honda M,et al.Peretinoin,an acyclic retinoid,suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet [J].Oncotarget,2017,8(25):39978-39993.
|
34 |
Bruix J, Qin S, Merle P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,389(10064):56-66.
|
35 |
Abou-Alfa GK, Meyer T, Cheng AL,et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].N Engl J Med,2018,379(1):54-63.
|
36 |
El-Khoueiry A B, Sangro B, Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial [J].Lancet,2017,389(10088):2492-2502.
|